Released Oct 28, 2026, before the open
10-Q filed Oct 28, 2026, 28 days after period end · 0000805928-26-000108
We closed an upsized public offering with the sale of 5,646,500 shares of common stock and receipt of $225 million of net proceeds.
The release| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $75.83M | $60.08M | $48.64M | $41.27M |
| Net Income | $2.33M | $708.00K | -$1.86M |
Axogen, Inc. · CIK 805928 · Engraved from SEC EDGAR
| -$4.09M |
| EPS Diluted | $0.04 | $0.01 | -$0.04 | -$0.10 |
|---|
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Axogen closed an upsized public offering with net proceeds of $225 million, and completed the acquisition of BioCircuit Technologies, Inc. on October 1, 2026.¶1¶2
Based on positive clinical study outcomes, Axogen decided to initiate Prostate market development beginning in 2027.¶3
For 2026, Axogen expects full-year revenue of at least $290 million, representing growth of at least 29%, and gross margin of at least 73%.¶4